Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
UNIVERSITY OF DUNDEE maintains a company patent portfolio with 3 pending office actions currently on record. These matters are located within the Biotechnology & Pharmaceuticals technology area. The prosecution is handled by 3 distinct examiners across 3 distinct art units, reflecting a varied administrative footprint.
The busiest examiner for the university is KUCKLA, ANNA GRACE, who is responsible for 1 busiest examiner pending action. While KUCKLA, ANNA GRACE is the busiest, the 3 pending office actions are evenly distributed among 3 distinct examiners. This means each examiner is currently reviewing exactly one matter for the portfolio.
The Biotechnology & Pharmaceuticals technology area encompasses all 3 distinct art units active for the university. With 3 pending office actions, the portfolio shows a steady level of engagement with the patent office. The 1 busiest examiner pending action is part of a broader prosecution effort involving 3 distinct examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCKLA, ANNA GRACE | 1 | 53.8% | +51.3% |
| SPANGLER, JOSEPH RANKIN | 1 | 40.8% | +70.6% |
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720366 | TARGETED DEGRADATION OF ALPHA-SYNUCLEIN | SPANGLER, JOSEPH RANKIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18859690 | ANTI-INFECTIVE AGENTS | KUCKLA, ANNA GRACE | — |
| 18720366 | TARGETED DEGRADATION OF ALPHA-SYNUCLEIN | SPANGLER, JOSEPH RANKIN | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1656 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18859690 | ANTI-INFECTIVE AGENTS | KUCKLA, ANNA GRACE | 1626 | §112 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18720366 | TARGETED DEGRADATION OF ALPHA-SYNUCLEIN | SPANGLER, JOSEPH RANKIN | 1656 | §102§103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18694524 | PROTEIN DEGRADER | AGGARWAL, SAHIL CHANDER | 1623 | §103§112DP | Non-Final OA | — | Pending | Mar 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITY OF DUNDEE has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Anna Grace Kuckla has the most, with 1 of UNIVERSITY OF DUNDEE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
